Your browser doesn't support javascript.
loading
Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial.
Zu, Yingling; Li, Zhen; Gui, Ruirui; Liu, Yanyan; Zhang, Yanli; Yu, Fengkuan; Zhao, Huifang; Fu, Yuewen; Zhan, Xinrong; Wang, Zhongliang; Xing, Pengtao; Wang, Xianjing; Wang, Huili; Zhou, Jian; Song, Yongping.
Afiliación
  • Zu Y; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, Henan, China.
  • Li Z; Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450000, Henan, China.
  • Gui R; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, Henan, China.
  • Liu Y; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, Henan, China.
  • Zhang Y; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, Henan, China.
  • Yu F; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, Henan, China.
  • Zhao H; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, Henan, China.
  • Fu Y; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, Henan, China.
  • Zhan X; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, Henan, China.
  • Wang Z; Department of Hematology, Central Hospital of Xinxiang, Xinxiang, 453000, Henan, China.
  • Xing P; Department of Hematology, Central Hospital of Xinxiang, Xinxiang, 453000, Henan, China.
  • Wang X; Department of Hematology, Central Hospital of Xinxiang, Xinxiang, 453000, Henan, China.
  • Wang H; Department of Hematology, The Third People's Hospital of Zhengzhou, Zhengzhou, 450000, Henan, China.
  • Zhou J; Department of Hematology, The Third People's Hospital of Zhengzhou, Zhengzhou, 450000, Henan, China.
  • Song Y; Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450000, Henan, China. zhoujiandoctor@163.com.
Bone Marrow Transplant ; 57(10): 1573-1580, 2022 10.
Article en En | MEDLINE | ID: mdl-35840747
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Trasplante de Células Madre de Sangre Periférica / Células Madre de Sangre Periférica / Enfermedad Injerto contra Huésped Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Trasplante de Células Madre de Sangre Periférica / Células Madre de Sangre Periférica / Enfermedad Injerto contra Huésped Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2022 Tipo del documento: Article País de afiliación: China